Actinium Pharma (AMEX:ATNM) Azioni

ACTINIUM PHARMACEUTICALS INC

Actinium Pharmaceuticals

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGRI

ATNM

ATPC

BJDX

CHGG

CNSP

HPAI

LCID

LUMN

PLTR

RXST

SERV

SMFG

SPWR

TENK

TPET

UPXI

Pre-market: Palantir guida i rialzi con un +9,6%, mentre SunPower e Chegg mostrano cali significativi. Scopri i dettagli.

Chi sale e chi scende: i maggiori movimenti nel pre-market di oggi

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharmaceuticals Inc

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#AMEX">ATNM</a>) with a Buy and maintains $4 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Actinium Pharma, Maintains $4 Price Target

The update featured the unveiling of ATNM-400, Actinium's new Actinium-225 (Ac-225) solid tumor program, which is a novel, non-PSMA targeting, first-in-class radiotherapy for prostate cancer. Initial preclinical data from ATNM-400 will be presented at AACR on April 27, 2025.

Actinium Provides Business Update Detailing Recent Achievements And Anticipated Milestones From Its Clinical Pipeline

<h3>Gainers</h3>
<ul>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) shares rose 246.0% to $0.2 during Wednesday's regular session. The market value of their outstanding shares is at $5.0 million. </li>
<li>OSR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) shares increased by 112.49% to $3.4. The market value of their outstanding shares is at $65.5 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) stock increased by 92.07% to $0.11. The company's market cap stands at $15.3 million. </li>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) stock increased by 46.09% to $0.99. The market value of their outstanding shares is at $3.8 million. </li>
<li>Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) stock increased by 21.36% to $0.11. The market value of their outstanding shares is at $1.8 million. </li>
<li>Actinium Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#AMEX">ATNM</a>) stock increased by 20.56% to $1.91. The company's market cap stands at $59.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Acrivon Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRV#NASDAQ">ACRV</a>) stock fell 39.1% to $3.28 during Wednesday's regular session. The market value of their outstanding shares is at $102.1 million. </li>
<li>Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) stock fell 29.92% to $2.02. The market value of their outstanding shares is at $259.2 million. </li>
<li>Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) shares decreased by 28.27% to $2.69. The market value of their outstanding shares is at $8.4 million. As per the press release, Q4 earnings came out 4 days ago. </li>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) stock declined by 21.02% to $0.59. The company's market cap stands at $8.0 million. </li>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) stock declined by 17.63% to $7.29. The market value of their outstanding shares is at $63.4 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares decreased by 16.87% to $0.66. The company's market cap stands at $47.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACON

ACRV

CRVO

CTOR

HUMA

OCEA

OSRH

PTPI

TNON

12 Health Care Stocks Moving In Wednesday's Intraday Session

WIIM

Actinium Pharmaceuticals shares are trading higher after the company announced it is going to present a business update at Trump Mar-a-Lago Club.

- Company to highlight recent significant progress made with its&nbsp;Actimab-A and Iomab-ACT clinical programs, leading-edge R&amp;D and radiopharmaceutical manufacturing infrastructure
- Revitalized clinical programs focused on 3 separate multi-billion-dollar market opportunities in myeloid malignancies, solid tumors and cell &amp; gene therapy conditioning with clinical data expected in 2025 supporting each addressable market
- Presentation follows Investor KOL Event and Company Update on March 25th
NEW YORK, March 26, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#NYSE">ATNM</a>) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, announced it will be presenting a business update today at Trump Mar-a-Lago Club, Florida. This presentation follows an Investor KOL Call and Company Update hosted by Actinium on Tuesday, March 25th highlighting its revitalized clinical programs and expanded market opportunities. Actinium's Investor KOL Call and Company Update can be accessed for replay <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4391613-1&amp;h=2186212444&amp;u=https%3A%2F%2Flifescievents.com%2Fevent%2Factinium-2%2F&amp;a=here">here</a>. &nbsp;

Events

Actinium Pharmaceuticals To Present Business Update At Trump Mar-A-Lago Club Today; Revitalized Clinical Programs Focused On 3 Separate Market Opportunities In Myeloid Malignancies, Solid Tumors And Cell & Gene Therapy Conditioning With Clinical Data Expected In 2025

Actinium Pharmaceuticals, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#NYSE">ATNM</a>) (Actinium or the Company), a pioneer in the development of targeted radiotherapies,&nbsp;today announced it has entered into an agreement for the supply of Actinium-225 (Ac-225) with Eckert &amp; Ziegler. Under this agreement, Actinium Pharmaceuticals will have access to Eckert &amp; Ziegler's high-quality Actinium-225 to further develop its lead product Actimab-A as well as additional early and late-stage development candidates for both U.S. and international clinical trials.
&nbsp;
Targeted radiotherapies using Ac-225 have shown great promise in the treatment of cancer. The radioisotope releases powerful alpha particles with high energy and low penetration depth, enabling precise targeting of tumor cells, including hard-to-reach micrometastases, while minimizing effects on surrounding healthy tissue. Actimab-A is an Ac-225 based radiotherapy agent, directed against CD33, a receptor overexpressed in patients with acute myeloid leukemia (AML) and other myeloid indications.

Biotech

General

Actinium Pharmaceuticals Enters Agreement With Eckert & Ziegler For Supply Of Actinium-225 To Develop Actimab-A And Other Candidates For U.S. And International Trials; Terms Not Disclose

Actinium Pharmaceuticals shares are trading higher after the company announced it entered a research collaboration with Memorial Sloan Kettering for clinical expansion of Actimab-A's backbone therapy strategy.

Contracts

Actinium Pharmaceuticals To Collaborate With Memorial Sloan Kettering For Clinical Expansion Of Actimab-A's Backbone Therapy Strategy

Actinium Pharmaceuticals Announces A Clinical Trial Program For Solid Tumors Combining Actimab-A With PD-1 Checkpoint Inhibitors KEYTRUDA And OPDIVO; Clinical Proof Of Concept Data Expected In 2025

-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Median Overall Survival of 18.4 months with Actimab-A + CLAG-M in patients with relapsed or refractory AML who received 1 or 2 lines of prior therapy
-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mutation agnostic potential of Actimab-A demonstrated by high rates of Complete Remissions and Measurable Residual Disease Negativity in patients with high-risk features including TP53 mutations and prior Venetoclax treatment
-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Actimab-A + CLAG-M combination yielded deep and clinically meaningful responses with expected and manageable safety profile supporting planned pivotal Phase 2/3 trial
NEW YORK, March 17, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#NYSE">ATNM</a>) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that results from the clinical trial evaluating Actimab-A in combination with the chemotherapy CLAG-M in patients with relapsed/refractory acute myeloid leukemia (r/r AML) have been published in the peer-reviewed journal Leukemia. The publication highlights data including long-term survival outcomes from two-year follow-up and better outcomes in high-risk patients. Actimab-A is a novel targeted radiotherapeutic that uses the Actinium-225 (Ac-225) isotope payload directed against CD33, a marker expressed ubiquitously on AML blasts. The trial was conducted at the Medical College of Wisconsin (MCW) which has extensive experience treating relapsed refractory AML patients with CLAG-M.
Actimab-A + CLAG-M Trial Data Highlights from Publication:
<ul>
<li>18.4 month median Overall Survival (OS) in patients who received 1 or 2 lines of prior therapy</li>
<li>52% of patients in the Actimab-A +CLAG-M trial had TP53 mutations, 56% had prior allogeneic stem cell transplant and 56% of patients had prior Venetoclax therapy</li>
<li>Actimab-A + CLAG-M outcomes compare favorably to the results from historical data with CLAG-M alone in the pre-Venetoclax era from MCW's study (median OS of 13.3 months). Typically, patients who have failed Venetoclax treatment demonstrate median survival between 2.4 – 4.6 months as reported in the literature and the patients with a TP53 mutation even have more dismal survival outcomes. Hence this data supports the use of Actimab-A plus CLAG-M for these patients.</li>
<li>Actimab-A + CLAG-M produced high rates of measurable residual disease negativity (MRD-) including 75% across all patients, 83.3% in patients with a TP53 mutation and 100% in patients with prior Venetoclax therapy</li>
<li>71% of eligible patients received a bone marrow transplant (BMT) and median OS in these patients was 24.05 months</li>
</ul>

Actinium Pharmaceuticals Announces Publication Of Actimab-A + CLAG-M Trial Results In Patients With Relapsed Or Refractory Acute Myeloid Leukemia In The Peer-Reviewed Journal Leukemia

Actinium Pharmaceuticals Initiates Actimab-A Triplet Combination Frontline Trial Under NCI CRADA

Stephens &amp; Co. analyst Sudan Loganathan reiterates Actinium Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#AMEX">ATNM</a>) with a Overweight and maintains $5 price target.

Stephens & Co. Reiterates Overweight on Actinium Pharma, Maintains $5 Price Target

Actinium Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#AMEX">ATNM</a>) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.30) by 23.33 percent. This is a 24.49 percent increase over losses of $(0.49) per share from the same period last year.

Earnings

Actinium Pharmaceuticals Q3 EPS $(0.37) Misses $(0.30) Estimate

<h3>Gainers</h3>
<ul>
<li>TFF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) stock moved upwards by 27.9% to $2.63 during Friday's pre-market session. The company's market cap stands at $9.1 million. </li>
<li>Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) stock rose 12.62% to $69.4. The market value of their outstanding shares is at $36.5 billion. As per the news, the Q3 earnings report came out today. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares rose 9.31% to $2.35. The market value of their outstanding shares is at $24.8 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares increased by 8.76% to $1.31. The company's market cap stands at $93.4 million. </li>
<li>Actinium Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#AMEX">ATNM</a>) shares increased by 8.33% to $1.82. The company's market cap stands at $56.7 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) shares rose 8.11% to $2.93. The market value of their outstanding shares is at $23.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) stock fell 23.9% to $24.85 during Friday's pre-market session. The company's market cap stands at $87.4 million. </li>
<li>Quince Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNCX#NASDAQ">QNCX</a>) stock declined by 15.97% to $1.0. The company's market cap stands at $43.2 million. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) stock declined by 14.89% to $0.31. The market value of their outstanding shares is at $4.0 million. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) shares decreased by 11.01% to $0.65. The company's market cap stands at $3.7 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) stock fell 10.11% to $4.27. The market value of their outstanding shares is at $5.6 million. </li>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) shares decreased by 9.91% to $0.58. The market value of their outstanding shares is at $35.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIVI

BNOX

DWTX

HEPA

MNPR

PASG

QNCX

TFFP

12 Health Care Stocks Moving In Friday's Pre-Market Session

Press Releases

ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Legal

ROSEN, A LONGSTANDING LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNM

ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit

Actinium Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights - ATNM

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNM

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNM

Shareholders that lost money on Actinium Pharmaceuticals, Inc.(ATNM) should contact The Gross Law Firm about pending Class Action - ATNM

Actinium Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights – ATNM

ATNM Stockholders Should Contact Robbins LLP for Information on How to Lead the Class Action Against Actinium Pharmaceuticals, Inc.

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Actinium Pharma

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

CytomX Therapeutics

Cue Biopharma

Dyadic International, Inc. - Common Stock

Dyadic International

Fortress Biotech

Gain Therapeutics

Immix Biopharma

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma

MAIA Biotechnology

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

OKYO Pharma

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

PepGen

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Rein Therapeutics

Repare Therapeutics

Skye Bioscience

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

X4 Pharmaceuticals

Xilio Therapeutics

HC Wainwright & Co.

Stephens & Co.

Maxim Group

Cantor Fitzgerald

B. Riley Securities

Screenshot 2024-02-29 at 7.16.11 PM

COEP

Here&#39;s How Coeptis Therapeutics Is Innovating Cell Therapy Approaches

Comments

Actinium Pharma

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO